myelofibrosis

News

CHMP backs GSK’s momelotinib for myelofibrosis

GSK is on the brink of EU approval for JAK inhibitor momelotinib as a treatment for myelofibrosis patients with anaemia, after the EMA’s human medicines committee issued a

News

GSK gets wide FDA approval for myelofibrosis drug

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquire

News

FDA delays review of GSK’s momelotinib for myelofibrosis

GSK won’t be hearing from the FDA this month about its marketing application for momelotinib as a treatment for myelofibrosis patients with anaemia after all.

News

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibro

News

GSK cancer division delivers good news after string of R&D s...

GSK has reported much-needed progress with two of its cancer therapies, with a phase 3 trial win for immunotherapy Jemperli in endometrial cancer and the start of a review in the EU for mye

News

GSK gets June 2023 FDA decision date for momelotinib

The clock is now ticking on the FDA's review of GSK's momelotinib for myelofibrosis patients with anaemia – the centrepiece of its $1.9 billion

CHMP backs GSK’s momelotinib for myelofibrosis

GSK gets wide FDA approval for myelofibrosis drug

FDA delays review of GSK’s momelotinib for myelofibrosis

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

GSK cancer division delivers good news after string of R&D s...

GSK gets June 2023 FDA decision date for momelotinib

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

myelofibrosis

Editor's Picks